Description: Metacrine is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).
Home Page: www.metacrine.com
MTCR Technical Analysis
3985 Sorrento Valley Boulevard
San Diego,
CA
92121
United States
Phone:
858 369 7800
Officers
| Name | Title |
|---|---|
| Dr. Preston S. Klassen M.D., M.H.S. | Pres, CEO & Director |
| Ms. Patricia Millican | Chief Financial Officer |
| Ms. Theresa Lowry | VP of HR |
| Mr. Michael B. York | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4043 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |